Actionable news
All posts from Actionable news
Actionable news in ABT: ABBOTT LABORATORIES,

Here Are All The Big Biotech Mergers In 2016

Pfizer, Inc. NYSE:PFE, Medivation, Inc. NASDAQ:MDVN - Here Are All The Big Biotech Mergers In 2016

Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares AGN 0.69%, Pfizer Inc. PFE 0.14% has returned to the M&A table with a bang.

Although some analysts and industry experts believe biotech firms enjoy an elevated premium or valuation, M&A in the space is growing. As a result, small companies have become the target of the big companies.

Most recently, Pfizer acquired Medivation Inc MDVN 0.14% for $14 billion on August 22. Within the next few days, the company bought AstraZeneca plc (ADR) AZN 0.54%'s antibiotics portfolio for $1.5 billion. There are also a number of small companies that announced M&A in the current year.

Related Link: BREAKING: Icahn Refutes Ackman's Claim, Buys 2.3 Million More Shares In Herbalife

Below is a look at the big mergers in the current year.

  • Abbott Laboratories ABT 0.33% announced an agreement to buy Alere Inc. ALR 2.8% for $5.8 billion on February 1. However, Alere has since announced that it is suing Abbot over the merger deal. Abbott has refuted the complaints and is "continuing with its efforts to acquire regulatory approvals."
  • Gilead Sciences, Inc. GILD 0.39% announced the acquisition of Nimbus Apollo, Inc., which was a wholly-owned subsidiary of Nimbus Therapeutics, and its Acetyl-CoA Carboxylase inhibitor program for $1.2 billion on April 4.
  • Cinven went into an agreement to acquire BioClinica for $1.4 billion on August 22.
  • Pfizer to buy Medivation for $14 billion, announced on August 22.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

© 2016 Benzinga does not provide investment advice. All rights reserved.